TrialCurveNCI9673 (Part B): reconstructed Kaplan–Meier curves
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | J Clin Oncol. 2026 Jan 7;44(6):497–507. doi: 10.1200/JCO-25-00929 |
|---|---|
| DOI | 10.1200/JCO-25-00929 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Nivo+Ipi 3.9 months; Nivo 2.8 months. Survival at 18 months: Nivo+Ipi 21%; Nivo 13%. Hazard ratio Nivo+Ipi vs Nivo 0.88 (95% CI 0.57–1.34).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivo+Ipi | 48 | 42 | 3.9 |
| Nivo | 52 | 46 | 2.8 |
- Nivo+Ipi vs Nivo: reconstructed HR 0.88 (95% CI 0.57–1.34)
Landmark survival (reconstructed)
| Time | Nivo+Ipi | Nivo |
|---|---|---|
| 6 mo | 33.3% | 17.3% |
| 12 mo | 27.1% | 13.5% |
| 18 mo | 20.8% | 13.5% |
| 24 mo | 14.1% | 11.5% |
| 36 mo | 11.7% | — |
| 48 mo | 11.7% | — |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.86, reconstructed 0.879 pass
Overall survival
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Nivo+Ipi 19.8 months; Nivo 15.7 months. Survival at 18 months: Nivo+Ipi 54%; Nivo 46%. Hazard ratio Nivo+Ipi vs Nivo 0.97 (95% CI 0.58–1.63).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivo+Ipi | 48 | 30 | 19.8 |
| Nivo | 52 | 28 | 15.7 |
- Nivo+Ipi vs Nivo: reconstructed HR 0.97 (95% CI 0.58–1.63)
Landmark survival (reconstructed)
| Time | Nivo+Ipi | Nivo |
|---|---|---|
| 6 mo | 78.7% | 72.9% |
| 12 mo | 72.0% | 59.9% |
| 18 mo | 54.4% | 45.6% |
| 24 mo | 31.9% | 37.1% |
| 36 mo | 28.7% | 31.8% |
| 48 mo | 21.5% | 15.9% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.98, reconstructed 0.97 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/nci9673-part-b-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/nci9673-part-b-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: J Clin Oncol. 2026 Jan 7;44(6):497–507. doi: 10.1200/JCO-25-00929 doi:10.1200/JCO-25-00929. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/nci9673-part-b
Report a problem with these data
Related trials
- PANTHEON: Overall survival from start of study; Progression-free survival of second-line therapy (pr
- CONFIRM: Overall survival; Progression-free survival
- ADIUVO: Overall survival; Recurrence-free survival
- VIM: Overall survival; Progression-free survival
- GENERATE: Overall survival (planned interim analysis); Overall survival (updated analysis); Progress
- Convalescent plasma for severe COVID-19 in cancer patients: Overall survival (secondary endpoint)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials